ReviewOncology and therapy2026
Repurposing Syrosingopine for Cancer Therapy: Lactate Trapping and ISR Sensitization as Metabolic Vulnerabilities.
Review in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCancer cells rewire their metabolism toward aerobic glycolysis (the Warburg effect), leading to lactate production that supports tumor growth, hypoxia adaptation, and immune evasion. In this context, syrosingopine, originally developed as an antihypertensive drug, has been repurposed as a dual inhibitor of the lactate transporters MCT1 and MCT4. This dual blockade promotes intracellular lactate accumulation, perturbs NAD
methodsWe conducted a narrative review of English-language publications on syrosingopine from 2016 to 2026, identified through PubMed and Scopus and supplemented by manual reference screening. Eligible studies investigated syrosingopine in the context of cancer biology, tumor metabolism, immunometabolism, therapeutic mechanisms, nanoformulations, or computational repurposing.
resultsPreclinical studies indicate that syrosingopine inhibits lactate efflux, reduces glycolytic flux, and depletes NAD
conclusionSyrosingopine exemplifies a preclinical "lactate trap"-based metabolic intervention with the potential to modulate integrated stress responses and immunometabolic pathways in glycolysis-dependent tumors. Its successful clinical repurposing will require biomarker-guided early-phase trials, optimization of nanoformulations and dosing strategies, incorporation of metabolic imaging readouts, and careful safety monitoring to address tissue-specific toxicities and metabolic plasticity. Graphical abstract available for this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.